Darren R. Feldman

TL;DR: A large-scale, prospective clinical sequencing initiative using a comprehensive assay, MSK-IMPACT, through which tumor and matched normal sequence data from a unique cohort of more than 10,000 patients with advanced cancer are compiled and identified clinically relevant somatic mutations, novel noncoding alterations, and mutational signatures that were shared by common and rare tumor types.

TL;DR: Cabozantinib demonstrated a significant clinical benefit in PFS and ORR over standard-of-care sunitinib as first-line therapy in patients with intermediate- or poor-risk mRCC.

TL;DR: A large retrospective analysis confirms the unacceptable incidence of TEEs in patients receiving cisplatin-based chemotherapy and calls for randomized studies to be urgently needed in this specific cancer population treated with cisplant-based regimens.

TL;DR: Clinical trials have led to evidence-based treatment recommendations for advanced testicular cancer based on risk stratification, and clinicians should be familiar with the potential complications of these therapies.

TL;DR: Recommendations for the management of adult patients with nonseminomatous GCTs, the most common solid tumor in men between the ages of 20 and 34 years, are focused on.